

growth factor in a pharmaceutically acceptable opthamalic carrier and is in a form selected from the group consisting of solutions, suspensions, ointments, gels, or creams.--

--15. The method of claim 13, wherein the composition is in a form selected from the group consisting of an ocular erodible insert, a polymeric membrane reservoir system to be placed in the conjunctival sac, or in combination with a local bandage and a therapeutic contact lens.--

--16. The method of claim 13 wherein the pathology affecting the internal tissues of an eye is selected from pathologies affecting the sclera, ciliary bodies, crystalline lens, retina, optic nerve, vitreous body, and choroidea.--

--17. The method of claim 16, wherein the pathology has a trophic, post-traumatic, infective, post-surgical, autoimmune, dystrophic, or degenerative origin, or is originated by laser treatment.--

--18. The method of claim 14, wherein the composition is in the form an opthamalic solution.--

--19. The method of claim 18, wherein the opthamalic solution contains from 200-250 µg/ml of nerve growth factor.--

--20. The method according to claim 13, wherein the nerve growth factor is of murine or human origin, or is a human recombinant nerve growth factor.--

--21. A method for the treatment or prophylaxis of pathologies affecting the internal tissues of the eye, excluding retinal pathologies and pathologies affecting the optic nerve, comprising the administration of a composition comprising nerve growth factor.--